Paris Cedex 20

• Early detection of triple negative breast cancer relapse (CUPCAKE) Not authorised
  2022-501562-22-00 4 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• Evaluation of the efficacy and safety of stiripentol in patients 6 years and older with primary hyperoxaluria type 1, 2 or 3 - CRYSTAL Pending
  2023-508062-15-00 5 Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
• Efficacy and tolerance of nicotinamide supplementation during acute kidney injury: a prospective randomized double-blind trial Pending
  2023-508664-30-00 5 Acute kidney injury
• Aspirin in acute pneumonia in the elderly: a multicenter, double-blind, randomized, placebo-controlled trial Pending
  2024-510811-32-00 5 acute pneumonia
• Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or … Pending
  2024-516052-17-01 10 Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
• TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma: A single-arm Phas … Pending
  2024-516182-37-01 4 Maintenance treatment in patients with locally advanced/metastatic uro
• A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient … Pending
  2024-517621-54-00 5 High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
• Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Duct … Pending
  2024-518139-12-00 4 locally advanced or metastatic Pancreatic ductal adenocarcinoma
• Lidocaine for opioid sparing in vaso-occlusive crisis of Sickle Cell Disease Pending
  2024-518437-28-00 5 Sickle cell disease
• Image-Verapamil SR in Adults with Type 1 Diabetes (Image-VER-A-T1D) Pending
  2024-518554-17-00 4 type 1 diabetes mellitus
• Study evaluating two treatment strategies for rectal cancer in patients ≥75 years old Pending
  2025-521619-37-00 5 Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
• IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after … Pending
  2025-521908-22-00 10 EGFR-mutated Non-small Cell Lung Cancer
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial Recruiting
  2024-514799-42-00 4 2024-11-05 IDIOPATHIC PULMONARY FIBROSIS
• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• Study assessing the efficacy of etoposide free chemotherapy plus durvalumab in first line extensive disease Small Cell Lung Cancer Recruiting
  2023-504670-38-00 4 2023-11-17 Extensive disease Small Cell Lung Cancer
• A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting
  2022-501007-28-00 5 2023-04-18 Breast Neoplasms
• A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan … Recruiting
  2023-505749-14-00 5 2022-03-20 c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
• A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting
  2023-509628-16-00 5 2026-05-07 Small Cell Lung Cancer (SCLC)
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o … Recruiting
  2024-515658-26-00 5 2026-01-21 Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
• Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting
  2022-501562-22-01 4 2026-01-05 Triple-negative breast cancer (TNBC) patients at high risk of relapse
• A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep … Recruiting
  2024-513586-39-00 5 2025-12-10 Prostate Cancer
• Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting
  2024-519971-25-00 5 2025-12-03 Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer

Showing 1–24 of 133 trials